SELLAS Life Sciences Group, Inc which can be found using ticker (SLS) have now 4 market analysts covering the stock. The analyst consensus now points to a rating of ‘Buy’. The range between the high target price and low target price is between 9 and 3 with the average target price sitting at $6.00. Given that the stocks previous close was at $1.46 this would imply there is now a potential upside of 311.0%. Also worth taking note is the 50 day moving average now sits at $2.24 and the 200 moving average now moves to $2.65. The company has a market cap of $44m. Company Website: https://www.sellaslifesciences.com
The potential market cap would be $180m based on the market consensus.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.
The company is not paying dividends at this time.
